Technology
Health
Pharmaceutical

Kiniksa Pharmaceuticals

$15.73
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.23 (-1.44%) Today
-$0.23 (-1.44%) Today

Why Robinhood?

You can buy or sell KNSA and other stocks, options, ETFs, and crypto commission-free!

About

Kiniksa Pharmaceuticals, Ltd. Class A Common Stock, also called Kiniksa Pharmaceuticals, is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Read More Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason, and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.

Employees
111
Headquarters
Hamilton, Hamilton
Founded
2015
Market Cap
789.85M
Price-Earnings Ratio
Dividend Yield
Average Volume
136.29K
High Today
$16.37
Low Today
$15.63
Open Price
$15.88
Volume
5.33K
52 Week High
$32.88
52 Week Low
$13.04

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
2018 IPO
North America (Non-US/Canada)
North America

News

Seeking AlphaMar 18

Kiniksa Pharmaceuticals (KNSA) Presents At American College of Cardiology's 68thAnnual Scientific Session - Slideshow

The following slide deck was published by Kiniksa Pharmaceuticals, Ltd. in conjunction with this event. 1 37 Click to enlarge Notes:...

18
PR NewswireFeb 27

Global Recurrent Pericarditis Maket Epidemiology and Market Forecasts 2017-2028: Rilonacept (Kiniksa Pharmaceuticals, Ltd.) is the First Immunosuppressant to be Launched in All of the 7 Major Markets

DUBLIN, Feb. 27, 2019 /PRNewswire/ -- The "Recurrent Pericarditis - Market Insights, Epidemiology and Market Forecast-2028" drug pipelines has been added to ResearchAndMarkets.com's offering. Recurrent Pericarditis - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Recurrent Pericarditis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan....

43

Earnings

-$0.97
-$0.79
-$0.62
-$0.44
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 9, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.